Puda Coal, Inc. (OTC BB: PUDC) specializes in providing premium grade cleaned coking coal to the steel manufacturing industry for the use in making coke in China. The company does this through its operating subsidiary, Shanxi Puda Coal Group Co., Ltd. The company has been growing at a very fast-pace and now provides nearly 50% of China’s coke. For further information, visit the company website at: www.pudacoalinc.com.
pSivida Corp. (NASDAQ: PSDV) has focused their efforts on developing drug delivery products, with an initial focus on ophthalmology and oncology. The company generates revenues through the marketing of the only two FDA approved sustained release back of the eye treatments for chronic eye disease. Substantial revenues are anticipated shortly from their varied late-stage product portfolio that includes a next generation product designed to treat Diabetic Macular Edema as well as other ophthalmic applications. For further information, visit the Company's web site at www.psivida.com.
Celsion Corporation (NASDAQ: CLN) is committed to developing and commercializing oncology drugs including tumor-targeting treatments. The company has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Hospital-Albert Einstein Medical School. By using technology that delivers high concentrations of anti-cancer agents directly the tumor site, they are able to maximize efficacy while minimizing side-effects common to cancer treatment. For further information, visit the Company's web site at www.celsion.com.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development stage company, is focused on safer, more effective, less invasive and more economical oncology and dermatology therapies. Currently, the company is conducting Phase 2 clinical trials of their proprietary drugs designed to treat psoriasis, metastatic melanoma, and atopic dermatitis. Provectus has developed multiple intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For further information, visit the Company's web site at www.pvct.com.
Cell Therapeutics, Inc. (NASDAQ: CTIC) is focused on leading the biopharmaceutical industry with their diversified portfolio of proprietary oncology drugs. They manage each and every aspect of the manufacturing process, but outsource their clinical and commercial active pharmaceutical ingredient (API) and finished product (FP) production activities to superior contract manufacturing organizations, both in the US and in Europe. For further information, visit the Company's web site at www.ctiseattle.com.
Protalex, Inc. (OTC BB: PRTX), a biotechnology company, is focused on developing a new class of drugs designed to treat a variety of autoimmune disorders. PRTX-100, the company’s lead compound, is currently being developed for a rare blood clotting disorder and rheumatoid arthritis. This compound is a highly-purified form of Staphylococcal Protein A (SpA or Protein A) and has been used in FDA-approved extracorporeal immunoadsorption systems for both idiopathic thrombocytopenic purpura and rheumatoid arthritis. For further information, visit the Company's web site at www.protalex.net.
Prospect Acquisition Corporation (AMEX: PAX) is a newly organized blank check company formed for the purpose of acquiring control of, through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, one or more businesses or assets in the financial service industry. On November 20, 2007 Prospect completed an initial public offering of 25,000,000 units at an offering price of $10.00 per unit, generating gross proceeds of $250,000,000. For further information, visit the company website at: www.prospectac.com.
Cell Genesys, Inc. (NASDAQ: CEGE) has their focus on developing and commercializing novel biological therapies for cancer patients. GVAX® cancer imunotherapy, the company's lead product platform, holds the potential to treat several types of cancer. Cell Genesys also holds an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. For further information, visit the Company's web site at www.cellgenesys.com.
Celgene Corporation (NASDAQ: CELG), a multinational biopharmaceutical company, is dedicated improving the lives of patients worldwide by delivering novel and life-changing drugs. Their aim is to build a major global biopharmaceutical corporation while discovering, developing, and commercializing products for the treatment of cancer and other severe, immune, inflammatory conditions. For further information, visit the Company's web site at www.celgene.com.
Pro-Pharmaceuticals, Inc. (AMEX: PRW), a development-stage company, is focused on the discovery, development, and commercialization of first-in-class, targeted therapeutic compounds designed to treat cancer, liver, microbial and inflammatory diseases. The company’s current focus is on developing a new generation of anti-cancer treatments by utilizing carbohydrate polymers to improve survival rates and improve the quality of life for cancer patients. For further information, visit the Company's web site at www.pro-pharmaceuticals.com.
